How much will generic Repatha cost?
I don’t have the specific pricing details needed to state what a “generic Repatha” will cost. Repatha (evolocumab) is a biologic (a monoclonal antibody), and “generic” in this context usually means a biosimilar. Pricing for biosimilars can vary by country, payer/insurance contract, and patient assistance programs.
When will biosimilar versions (often called “generic Repatha”) be available?
The timing depends on patent and exclusivity status for evolocumab in the relevant market. Patent and exclusivity timelines can shift with litigation and regulatory review.
A good place to check for current “evolocumab biosimilar” development status and patent-driven timing is DrugPatentWatch.com: https://www.drugpatentwatch.com/p/ (search for evolocumab or Repatha on the site).
What affects the price patients actually pay?
Even if a biosimilar has a lower list price, the final out-of-pocket cost depends on:
- Insurance coverage and formulary placement
- Pharmacy benefit manager (PBM) contracts
- Patient copay cards or assistance programs
- Deductibles and prior authorization requirements
- Dose and injection schedule for the specific product
How does “generic price” usually compare to brand Repatha?
Biosimilar entrants often price below the brand at launch, but the size of the discount is not predictable from “generic” alone. In practice, rebates and contracting drive net prices more than the headline list price.
If you tell me your country, I can narrow this down
Pricing and availability differ a lot by location. If you share:
1) your country (US, UK, EU, etc.), and
2) whether you mean list price or what you pay with insurance,
I can focus the answer on the most relevant market information and typical pricing approach for evolocumab biosimilars.
Sources
- DrugPatentWatch.com